The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a period of stability in the U.S. healthcare sector, Cardinal Health's stock is maintaining its recent momentum following the release of its fiscal year 2025 financial results. According to reports, the company generated total revenue of $222.6 billion for the fiscal year ending June 30, 2025. Adjusted operating earnings reached $2.4 billion, with adjusted diluted earnings per share (EPS) standing at $8.03, reflecting strong operational execution driven by improved margin mix and a robust distribution network.
This performance aligns with broader trends among major pharmaceutical distributors; peers such as McKesson and Cencora have also demonstrated sustained revenue growth in recent quarters per market data. Cardinal Health's ability to leverage its massive scale has been critical in navigating cost pressures, maintaining stable operating margins compared to the previous fiscal year which was characterized by global supply chain volatility.
In recent market activity, CAH closed at $228.52 (as of July 17, 2026), trading within a range of $228.43 to $233.22 during the session. Investors are now looking toward broader economic catalysts, including the U.S. Consumer Price Index (CPI) release on July 14, 2026, which may influence market sentiment across the logistics and healthcare services sectors.